| Monir Tabbosha, MD | |
|
9250 Blue Ash Rd, Blue Ash, OH 45242-6822 | |
| (513) 792-7443 | |
| (513) 791-4042 |
| Full Name | Monir Tabbosha |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 24 Years |
| Location | 9250 Blue Ash Rd, Blue Ash, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780849539 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 35.130725 (Ohio) | Primary |
| 207T00000X | Neurological Surgery | E8249 (Arkansas) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Christ Hospital | Cincinnati, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Beacon Orthopaedics And Sports Medicine Ltd | 0345136412 | 438 |
| Beacon Orthopaedics And Sports Medicine Ltd | 0345136412 | 438 |
News Archive
Almost 10 percent of the nation's entire population live with substance use disorder, but many struggle to find the right help – a task which is made more difficult because there is no standardized rating system to ensure the quality of care within specialized drug treatment facilities.
In recognition of its Centennial, the Johns Hopkins Bloomberg School of Public Health has compiled a list of 100 objects that tell some of the most compelling stories of public health over the last century and help us appreciate its vast reach.
Onconova Therapeutics, Inc., a development-stage pharmaceutical company focused on discovering and developing novel small molecule drug products to treat cancer, today announced that tolerability and favorable anti-tumor activity data from a Phase 1 trial evaluating oral rigosertib, a dual pathway inhibitor, in patients with advanced solid tumors including refractory metastatic head and neck cancer were presented today at the American Association for Cancer Research Annual Meeting.
Anavex Life Sciences Corp. today announced screening of the first healthy volunteers for the Phase I clinical study of ANAVEX 2-73, its lead compound for the treatment of Alzheimer's disease. ANAVEX 2-73 is the first of a new class of wholly-owned, oral, disease-modifying compounds, which act through sigma-1 receptor agonist as well as muscarinic cholinergic effects and up-regulation of Bcl-2.
› Verified 9 days ago
| Entity Name | Beacon Orthopaedics & Sports Medicine Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386670065 PECOS PAC ID: 0345136412 Enrollment ID: O20040225000690 |
News Archive
Almost 10 percent of the nation's entire population live with substance use disorder, but many struggle to find the right help – a task which is made more difficult because there is no standardized rating system to ensure the quality of care within specialized drug treatment facilities.
In recognition of its Centennial, the Johns Hopkins Bloomberg School of Public Health has compiled a list of 100 objects that tell some of the most compelling stories of public health over the last century and help us appreciate its vast reach.
Onconova Therapeutics, Inc., a development-stage pharmaceutical company focused on discovering and developing novel small molecule drug products to treat cancer, today announced that tolerability and favorable anti-tumor activity data from a Phase 1 trial evaluating oral rigosertib, a dual pathway inhibitor, in patients with advanced solid tumors including refractory metastatic head and neck cancer were presented today at the American Association for Cancer Research Annual Meeting.
Anavex Life Sciences Corp. today announced screening of the first healthy volunteers for the Phase I clinical study of ANAVEX 2-73, its lead compound for the treatment of Alzheimer's disease. ANAVEX 2-73 is the first of a new class of wholly-owned, oral, disease-modifying compounds, which act through sigma-1 receptor agonist as well as muscarinic cholinergic effects and up-regulation of Bcl-2.
› Verified 9 days ago
| Entity Name | Christ Hospital Orthopedic Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376859181 PECOS PAC ID: 1456477355 Enrollment ID: O20100929000030 |
News Archive
Almost 10 percent of the nation's entire population live with substance use disorder, but many struggle to find the right help – a task which is made more difficult because there is no standardized rating system to ensure the quality of care within specialized drug treatment facilities.
In recognition of its Centennial, the Johns Hopkins Bloomberg School of Public Health has compiled a list of 100 objects that tell some of the most compelling stories of public health over the last century and help us appreciate its vast reach.
Onconova Therapeutics, Inc., a development-stage pharmaceutical company focused on discovering and developing novel small molecule drug products to treat cancer, today announced that tolerability and favorable anti-tumor activity data from a Phase 1 trial evaluating oral rigosertib, a dual pathway inhibitor, in patients with advanced solid tumors including refractory metastatic head and neck cancer were presented today at the American Association for Cancer Research Annual Meeting.
Anavex Life Sciences Corp. today announced screening of the first healthy volunteers for the Phase I clinical study of ANAVEX 2-73, its lead compound for the treatment of Alzheimer's disease. ANAVEX 2-73 is the first of a new class of wholly-owned, oral, disease-modifying compounds, which act through sigma-1 receptor agonist as well as muscarinic cholinergic effects and up-regulation of Bcl-2.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Monir Tabbosha, MD 9250 Blue Ash Rd, Blue Ash, OH 45242-6822 Ph: (513) 792-7443 | Monir Tabbosha, MD 9250 Blue Ash Rd, Blue Ash, OH 45242-6822 Ph: (513) 792-7443 |
News Archive
Almost 10 percent of the nation's entire population live with substance use disorder, but many struggle to find the right help – a task which is made more difficult because there is no standardized rating system to ensure the quality of care within specialized drug treatment facilities.
In recognition of its Centennial, the Johns Hopkins Bloomberg School of Public Health has compiled a list of 100 objects that tell some of the most compelling stories of public health over the last century and help us appreciate its vast reach.
Onconova Therapeutics, Inc., a development-stage pharmaceutical company focused on discovering and developing novel small molecule drug products to treat cancer, today announced that tolerability and favorable anti-tumor activity data from a Phase 1 trial evaluating oral rigosertib, a dual pathway inhibitor, in patients with advanced solid tumors including refractory metastatic head and neck cancer were presented today at the American Association for Cancer Research Annual Meeting.
Anavex Life Sciences Corp. today announced screening of the first healthy volunteers for the Phase I clinical study of ANAVEX 2-73, its lead compound for the treatment of Alzheimer's disease. ANAVEX 2-73 is the first of a new class of wholly-owned, oral, disease-modifying compounds, which act through sigma-1 receptor agonist as well as muscarinic cholinergic effects and up-regulation of Bcl-2.
› Verified 9 days ago